US biotech company Palatin Technologies (NYSE: PTN) has terminated the license and collaboration agreement with Hungary's largest pharma company Gedeon Richter (RICHT: HB) for bremelanotide to treat female sexual dysfunction.
All rights and licenses granted to Richter have terminated and reverted back to Palatin, with no payment or reimbursement obligations as a result of this termination.
The license agreement began in August 2014 to co-develop and commercialize bremelanotide for female sexual dysfunction in the European Union, other European countries and additional selected countries. As per the terms of the agreement, Palatin received $9.8 million in total upfront payments from Richter, and a milestone payment of $3.1 million upon the initiation of Phase III clinical trials in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze